GLP-1 Market
LLY $1431.76 ▼ -0.0% NVO $40.82 ▲ +0.3% PFE $29.23 ▼ -0.5% VKTX $28.92 ▲ +0.9% KLRA $14.29 ▲ +0.4% GPCR $21.30 ▼ -2.0% RHHBY $61.06 ▼ -0.4%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Imiglucerase

Company
Sanofi
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
3 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

3 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for Imiglucerase and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT00358943

    International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

    Genzyme, a Sanofi Company 12000 participants Est. completion 2034-01-31 317 sites
    Other conditions: Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease
    View official trial listing →
  • Recruiting NCT NCT05518617

    Molecular and Functional Imaging in Monogenic PD.

    University of Exeter 45 participants Est. completion 2026-06-30 1 site
    Other conditions: Parkinson Disease, Nervous System Disorder, Neurodegenerative Diseases, Neurodegenerative Disease, Hereditary, Parkinson's
    View official trial listing →
  • Recruiting NCT NCT06869499

    Study of the Prevalence of Acid Sphingomyelinase Deficiency/Niemann Pick AB and B Disease in Patients With Diffuse Interstitial Lung Disease

    Not yet reported Wladimir MAUHIN, Dr 200 participants Est. completion 2029-03-01 1 site
    Other conditions: Splenomegaly, Splenectomy, Thrombopenia, Interstitial Lung Disease (ILD), Hypocholesterolemia
    View official trial listing →
  • Enrolling by invitation NCT NCT00001215

    Genetic Studies of Lysosomal Storage Disorders

    National Human Genome Research Institute (NHGRI) 1000 participants 1 site
    Other conditions: Lysosomal Storage Disorders, Gaucher Disease, Parkinson Disease
    View official trial listing →
  • Completed NCT NCT00001234

    Gene Therapy for Gaucher's and Fabry Disease Using Viruses and Blood-Forming Cells

    Not yet reported National Institute of Neurological Disorders and Stroke (NINDS) 120 participants Est. completion 2002-04 1 site
    Other conditions: Gaucher's Disease
    View official trial listing →
  • Completed NCT NCT00001289

    Effects of Enzyme Replacement in Gaucher's Disease

    National Institute of Neurological Disorders and Stroke (NINDS) 70 participants Est. completion 2008-03-03 1 site
    Other conditions: Gaucher's Disease
    View official trial listing →
  • Completed NCT NCT00001410

    PEG-Glucocerebrosidase for the Treatment of Gaucher Disease

    Not yet reported National Institute of Mental Health (NIMH) 18 participants Est. completion 2001-12 1 site
    Other conditions: Gaucher's Disease
    View official trial listing →
  • Completed NCT NCT00001416

    Bone Response to Enzyme Replacement in Gaucher's Disease

    Not yet reported National Institute of Neurological Disorders and Stroke (NINDS) 100 participants Est. completion 2000-11 1 site
    Other conditions: Gaucher's Disease
    View official trial listing →
  • Status unknown NCT NCT00004293

    Phase II Study of Glucocerebrosidase in Patients With Gaucher Disease

    Not yet reported National Center for Research Resources (NCRR) 24 participants 1 site
    Other conditions: Gaucher's Disease
    View official trial listing →
  • Completed NCT NCT00004294

    Phase I Study of Retrovirally Mediated Transfer of the Human Glucocerebrosidase Gene Into Peripheral Blood Stem Cells for Autologous Transplantation in Patients With Type I Gaucher Disease

    Not yet reported National Center for Research Resources (NCRR) 15 participants 1 site
    Other conditions: Gaucher's Disease
    View official trial listing →
  • Completed NCT NCT00244582

    Convection-Enhanced Delivery of Glucocerebrosidase to Treat Type 2 Gaucher Disease

    National Institute of Neurological Disorders and Stroke (NINDS) 1 participants Est. completion 2006-11-03 1 site
    Other conditions: Type 2 Gaucher Disease
    View official trial listing →
  • Completed NCT NCT00258778

    Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD)

    Not yet reported Protalix 6 participants Est. completion 2006-01
    Other conditions: Gaucher Disease
    View official trial listing →
  • Completed NCT NCT00302146

    Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations

    National Human Genome Research Institute (NHGRI) 64 participants 1 site
    Other conditions: Parkinson Disease, Gaucher Disease
    View official trial listing →
  • Completed NCT NCT00358150

    A Study of the Efficacy and Safety of Eliglustat Tartrate (Genz-112638) in Type 1 Gaucher Patients

    Not yet reported Genzyme, a Sanofi Company 26 participants Est. completion 2015-12 17 sites Stand-alone
    Other conditions: Gaucher Disease, Type 1, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease, Gaucher Disease, Non-Neuronopathic Form
    View official trial listing →
  • Completed NCT NCT00364858

    Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease

    Not yet reported Genzyme, a Sanofi Company 95 participants Est. completion 2007-02 26 sites
    Other conditions: Gaucher Disease, Type 1, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease, Gaucher Disease, Non-Neuronopathic Form
    View official trial listing →
  • Completed NCT NCT00365131

    A Multicenter Study of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease.

    Not yet reported Genzyme, a Sanofi Company 40 participants Est. completion 2004-07 1 site
    Other conditions: Gaucher Disease Type I, Cerebroside Lipidosis Syndrome, Clucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease, Gaucher Disease, Non-Neuronopathic Form
    View official trial listing →
  • Completed NCT NCT00376168

    A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease

    Not yet reported Pfizer 32 participants Est. completion 2009-10 11 sites
    Other conditions: Gaucher Disease
    View official trial listing →
  • Completed NCT NCT00391625

    Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT)

    Not yet reported, Not yet reported Shire 10 participants Est. completion 2008-01-31 3 sites
    Other conditions: Gaucher Disease
    View official trial listing →
  • Completed NCT NCT00430625

    A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease

    Not yet reported Shire 25 participants Est. completion 2009-04-01 5 sites
    Other conditions: Gaucher Disease, Type 1
    View official trial listing →
  • Completed NCT NCT00478647

    Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase

    Not yet reported, Not yet reported Shire 40 participants Est. completion 2009-06-26 15 sites
    Other conditions: Gaucher Disease
    View official trial listing →
  • Completed NCT NCT00553631

    Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease

    Not yet reported Shire 34 participants Est. completion 2009-05-05 11 sites
    Other conditions: Gaucher Disease, Type 1
    View official trial listing →
  • Completed NCT NCT00635427

    An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease

    Not yet reported Shire 95 participants Est. completion 2012-12-28 21 sites Stand-alone
    Other conditions: Gaucher Disease, Type 1
    View official trial listing →
  • Completed NCT NCT00705939

    Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial

    Not yet reported Pfizer 45 participants Est. completion 2013-08 11 sites
    Other conditions: Gaucher Disease
    View official trial listing →
  • Completed NCT NCT00712348

    Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase

    Not yet reported Pfizer 31 participants Est. completion 2013-05 10 sites
    Other conditions: Gaucher Disease
    View official trial listing →
  • Completed NCT NCT00891202

    A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)

    Not yet reported Genzyme, a Sanofi Company 40 participants Est. completion 2016-01 18 sites
    Other conditions: Gaucher Disease, Type 1
    View official trial listing →
  • Completed NCT NCT00943111

    A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)

    Not yet reported Genzyme, a Sanofi Company 160 participants Est. completion 2015-06 34 sites
    Other conditions: Gaucher Disease, Type 1
    View official trial listing →
  • Approved For Marketing NCT NCT00954460

    Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease

    Shire 32 sites
    Other conditions: Gaucher Disease, Type 1
    View official trial listing →
  • No Longer Available NCT NCT00962260

    Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease

    Pfizer 15 sites
    Other conditions: Gaucher Disease
    View official trial listing →
  • Completed NCT NCT01074944

    A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease to Evaluate Once Daily Versus Twice Daily Dosing (EDGE)

    Not yet reported Genzyme, a Sanofi Company 170 participants Est. completion 2015-10 46 sites
    Other conditions: Gaucher Disease
    View official trial listing →
  • Completed NCT NCT01132690

    A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease

    Not yet reported Pfizer 11 participants Est. completion 2012-07 3 sites
    Other conditions: Gaucher Disease
    View official trial listing →
  • Completed NCT NCT01136304

    Validating a New Severity Score System for Adults With Type 1 Gaucher Disease (GD1)

    University Research Foundation for Lysosomal Storage Diseases, Inc. 173 participants Est. completion 2013-12 2 sites
    Other conditions: Gaucher Disease
    View official trial listing →
  • Withdrawn NCT NCT01161914

    The Safety and Efficacy Study of ISU302 in Patient With Type I Gaucher Disease

    Not yet reported ISU Abxis Co., Ltd.
    Other conditions: Gaucher Disease
    View official trial listing →
  • Status unknown NCT NCT01344096

    Thrombocytopathy in Gaucher Disease Patients

    Rabin Medical Center 70 participants Est. completion 2018-11 2 sites
    Other conditions: Gaucher Disease, Thrombocytopathy
    View official trial listing →
  • Completed NCT NCT01411228

    A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease

    Not yet reported Pfizer 15 participants Est. completion 2014-08 3 sites
    Other conditions: Gaucher Disease
    View official trial listing →
  • Completed NCT NCT01614574

    Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease

    Not yet reported Shire 6 participants Est. completion 2013-05-25 3 sites
    Other conditions: Gaucher Disease
    View official trial listing →
  • Completed NCT NCT01685216

    Efficacy and Safety Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher Disease

    Not yet reported, Not yet reported Shire 7 participants Est. completion 2015-03-15 5 sites
    Other conditions: Gaucher Disease, Type 3
    View official trial listing →
  • Status unknown NCT NCT01716741

    Identification of Undiagnosed Gaucher Disease

    Not yet reported Brigham and Women's Hospital 100 participants 1 site
    Other conditions: Gaucher Disease
    View official trial listing →
  • Completed NCT NCT01747980

    Safety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease Patients

    Not yet reported Protalix 16 participants Est. completion 2014-03 2 sites
    Other conditions: Gaucher Disease
    View official trial listing →
  • Completed NCT NCT01842841

    Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher Disease

    Not yet reported Shire 5 participants Est. completion 2014-10-08 5 sites
    Other conditions: Gaucher Disease
    View official trial listing →
  • Completed NCT NCT01881633

    A Study of the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy Volunteers

    Not yet reported ISU Abxis Co., Ltd. 24 participants Est. completion 2010-11
    Other conditions: Gaucher Disease
    View official trial listing →
  • Status unknown NCT NCT01951989

    Intra-monocyte Imiglucerase Kinetics in Gaucher Disease

    Not yet reported University Hospital, Clermont-Ferrand 60 participants Est. completion 2016-06 1 site Stand-alone
    Other conditions: Gaucher Disease
    View official trial listing →
  • Completed NCT NCT02053896

    A Switch-Over Study of the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease

    ISU Abxis Co., Ltd. 5 participants Est. completion 2012-02
    Other conditions: Gaucher Disease
    View official trial listing →
  • Completed NCT NCT02107846

    An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112

    Not yet reported Protalix 10 participants Est. completion 2015-12 1 site
    Other conditions: Gaucher Disease
    View official trial listing →
  • Withdrawn NCT NCT02528617

    The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease

    Not yet reported Baylor Research Institute Est. completion 2017-10 1 site
    Other conditions: Gaucher Disease Type 1, Gaucher Disease Type 3
    View official trial listing →
  • Completed NCT NCT02574286

    Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher Disease

    Not yet reported Shire 21 participants Est. completion 2020-11-30 15 sites
    Other conditions: Gaucher Disease
    View official trial listing →
  • Completed NCT NCT02770625

    Phase III Study of ISU302 in Patients With Type 1 Gaucher Disease

    Not yet reported ISU Abxis Co., Ltd. 8 participants Est. completion 2014-08
    Other conditions: Gaucher Disease, Type 1
    View official trial listing →
  • Active, not recruiting NCT NCT02843035

    Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension

    Not yet reported Genzyme, a Sanofi Company 12 participants Est. completion 2026-10-30 7 sites Stand-alone
    Other conditions: Gaucher Disease Type 1, Gaucher Disease Type 3
    View official trial listing →
  • Terminated NCT NCT02906020

    A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation

    Not yet reported Genzyme, a Sanofi Company 273 participants Est. completion 2021-05-27 52 sites
    Other conditions: Parkinson's Disease
    View official trial listing →
  • Completed NCT NCT03485677

    Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3

    Not yet reported Sanofi 57 participants Est. completion 2025-12-26 21 sites Stand-alone
    Other conditions: Gaucher's Disease Type I, Gaucher's Disease Type III
    View official trial listing →
  • Completed NCT NCT03519646

    Eliglustat on Gaucher Disease Type IIIB

    Not yet reported National Taiwan University Hospital 4 participants Est. completion 2020-09-11 1 site
    Other conditions: Gaucher Disease, Type III
    View official trial listing →
  • Completed NCT NCT03702361

    Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) in Treatment-naive Patients With Type 1 Gaucher Disease

    Not yet reported Shaare Zedek Medical Center 15 participants Est. completion 2021-03-18 1 site
    Other conditions: Primary Disease
    View official trial listing →
  • Status unknown NCT NCT03811496

    Biomarker Analysis for GBA Associated Parkinson's Disease

    Lysosomal and Rare Disorders Research and Treatment Center, Inc. 100 participants Est. completion 2020-07 1 site
    Other conditions: Parkinson Disease, Gaucher Disease
    View official trial listing →
  • Completed NCT NCT04120506

    Long Term Impact of Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV)

    Not yet reported Shaare Zedek Medical Center 15 participants Est. completion 2022-01-01
    Other conditions: Gaucher Disease, Type 1
    View official trial listing →
  • Active, not recruiting NCT NCT04127578

    Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)

    Not yet reported, Not yet reported Prevail Therapeutics 32 participants Est. completion 2031-08-31 15 sites
    Other conditions: Parkinson Disease
    View official trial listing →
  • Terminated NCT NCT04145037

    Lentiviral Vector Gene Therapy - The Guard1 Trial of AVR-RD-02 for Subjects With Type 1 Gaucher Disease

    Not yet reported, Not yet reported AVROBIO 8 participants Est. completion 2023-08-21 5 sites
    Other conditions: Gaucher Disease
    View official trial listing →
  • Completed NCT NCT04228172

    Genotypic Influences on Network Progression in Parkinson's Disease

    Northwell Health 17 participants Est. completion 2026-03-07 1 site
    Other conditions: Parkinson's Disease
    View official trial listing →
  • Completed NCT NCT04268030

    High Order Spectral Analysis of Local Field Potential Data on a Subgroup of Parkinson's Disease Patients Who Are Carriers of Mutations in the Glucocerebrosidase (GBA) Gene Undergoing DBS Electrode Placement

    Rush University Medical Center 9 participants Est. completion 2020-08-30 1 site
    Other conditions: Parkinson Disease
    View official trial listing →
  • Completed NCT NCT04370665

    Blood-Brain-Barrier Disruption With Cerezyme in Patient's With Parkinson's Disease

    Not yet reported InSightec 4 participants Est. completion 2022-02-25 1 site Stand-alone
    Other conditions: Parkinson Disease
    View official trial listing →
  • Active, not recruiting NCT NCT04411654

    Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)

    Not yet reported, Not yet reported Prevail Therapeutics 7 participants Est. completion 2027-02 6 sites
    Other conditions: Gaucher Disease, Type 2
    View official trial listing →
  • Completed NCT NCT04656600

    Study to Evaluate Efficacy and Safety of Imiglucerase Treatment in Chinese Patients With Gaucher Disease Type Ⅲ

    Not yet reported Sanofi 12 participants Est. completion 2023-10-12 5 sites Stand-alone
    Other conditions: Gaucher's Disease
    View official trial listing →
  • Completed NCT NCT04787887

    A Phase I Study to Compare Abcertin and EU-sourced Cerezyme® in Healthy Volunteers

    Not yet reported ISU Abxis Co., Ltd. 42 participants Est. completion 2020-10-26 1 site
    Other conditions: Gaucher Disease
    View official trial listing →
  • Active, not recruiting NCT NCT05222906

    Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3

    Not yet reported Sanofi 43 participants Est. completion 2026-10-30 22 sites
    Other conditions: Gaucher's Disease Type III
    View official trial listing →
  • Completed NCT NCT05287503

    Ambroxol as a Disease-modifying Treatment in GBA-PD

    Not yet reported Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta 65 participants Est. completion 2024-12-20 3 sites
    Other conditions: Parkinson Disease, GBA Gene Mutation
    View official trial listing →
  • Completed NCT NCT05304195

    Exploration of GCase Activity to Identify a Subpopulation Eligible for a Therapeutic Trial in Dementia With Lewy Bodies

    Assistance Publique - Hôpitaux de Paris 236 participants Est. completion 2026-06-17 1 site
    Other conditions: Dementia With Lewy Bodies
    View official trial listing →
  • Completed NCT NCT05529992

    A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease

    Not yet reported Takeda 20 participants Est. completion 2024-08-05 10 sites
    Other conditions: Gaucher Disease
    View official trial listing →
  • Active, not recruiting NCT NCT05565443

    MR-guided Focused Ultrasound Plus GCase

    Not yet reported InSightec 14 participants Est. completion 2028-12-31 1 site
    Other conditions: Parkinsons Disease
    View official trial listing →
  • Withdrawn NCT NCT05815004

    An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3

    Not yet reported, Not yet reported AVROBIO Est. completion 2027-12
    Other conditions: Gaucher Disease, Type 3
    View official trial listing →
  • Completed NCT NCT05819359

    Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

    Not yet reported Bial R&D Investments, S.A. 273 participants Est. completion 2026-09-09 95 sites
    Other conditions: Parkinson's Disease
    View official trial listing →
  • Status unknown NCT NCT06167603

    Exploring Brain Molecular Imaging and Blood Biomarkers in Subjects With Glucocerebrosidase Mutations: Toward a Precision Medicine Approach to Characterize Parkinson's Disease Clinical Trajectories

    IRCCS San Raffaele 140 participants Est. completion 2026-04-01 1 site
    Other conditions: Parkinson Disease
    View official trial listing →
  • Terminated NCT NCT06193421

    High-Dose Ambroxol in GBA1-Related Parkinson

    Not yet reported, Not yet reported Agyany Pharma LTD 46 participants Est. completion 2026-04-30 1 site
    Other conditions: Parkinson Disease, GBA Gene Mutation
    View official trial listing →
  • Status unknown NCT NCT06451419

    Non Motor Symptoms in Glucocerebrosidase-related Parkinson's Disease

    Juan Pablo Romero. MD, PhD 40 participants Est. completion 2026-08-31 2 sites
    Other conditions: Parkinson Disease
    View official trial listing →
  • Not yet recruiting NCT NCT07927140

    The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric Participants 2 to 11 Years of Age With Gaucher Disease Type 3 (GD3)

    Not yet reported Sanofi 18 participants Est. completion 2031-03-03
    Other conditions: Gaucher's Disease Type III
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Imiglucerase, Cerezyme

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.